Suggested Topics within your search.
Showing 1 - 16 results of 16 for search '', query time: 0.06s Refine Results
  1. 1
    Facilitating Collaborations to Develop Combination Investigational Cancer Therapies : Workshop Summary

    Facilitating Collaborations to Develop Combination Investigational Cancer Therapies : Workshop Summary

    Published 2012
    Full text (MCPHS users only)
    Electronic eBook
    Save to List
    Saved in:
  2. 2
    Advances in Combination Therapy for Asthma and COPD.

    Advances in Combination Therapy for Asthma and COPD. by Lotvall, Jan

    Published 2011
    Full text (MCPHS users only)
    Electronic eBook
    Save to List
    Saved in:
  3. 3
    The top 100 drug interactions : a guide to patient management

    The top 100 drug interactions : a guide to patient management by Hansten, Philip D.

    2016 edition.
    Published 2016
    Book
    Save to List
    Saved in:
  4. 4
    Pharmacoeconomic review report. Mifepristone and misoprostol (Mifegymiso).

    Pharmacoeconomic review report. Mifepristone and misoprostol (Mifegymiso).

    Published 2017
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  5. 5
    Clinical review report. Mifepristone and misoprostol (Mifegymiso).

    Clinical review report. Mifepristone and misoprostol (Mifegymiso).

    Published 2017
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  6. 6
    Clinical review report. Dolutegravir (Tivicay).

    Clinical review report. Dolutegravir (Tivicay).

    Published 2014
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  7. 7
    Empagliflozin (Jardiance).

    Empagliflozin (Jardiance).

    Published 2015
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  8. 8
    Dual antiplatelet therapy following percutaneous coronary intervention. A review of the clinical impact of treatment duration

    Dual antiplatelet therapy following percutaneous coronary intervention. A review of the clinical impact of treatment duration by Wells, George A.

    Published 2017
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  9. 9
    Dual antiplatelet therapy following percutaneous coronary intervention : clinical and economic impact of standard versus extended duration -- project protocol.

    Dual antiplatelet therapy following percutaneous coronary intervention : clinical and economic impact of standard versus extended duration -- project protocol.

    Published 2018
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  10. 10
    Health economic analysis of bevacizumab + paclitaxel versus paclitaxel alone as first-line treatment for metastatic breast cancer

    Health economic analysis of bevacizumab + paclitaxel versus paclitaxel alone as first-line treatment for metastatic breast cancer by Movik, Espen, Hamidi, Vida, Natvig Norderhaug, Inger, Klemp, Marianne

    Published 2009
    Full text
    Electronic eBook
    Save to List
    Saved in:
  11. 11
    Pharmacoeconomic review report. Levodopa/Carbidopa (Duodopa) (Abbvie Corporation) : indication : for the treatment of patients with advanced levodopa-responsive Parkinson's disease.

    Pharmacoeconomic review report. Levodopa/Carbidopa (Duodopa) (Abbvie Corporation) : indication : for the treatment of patients with advanced levodopa-responsive Parkinson's disease...

    Published 2018
    Full text
    Electronic eBook
    Save to List
    Saved in:
  12. 12
    Clinical review report. Ticagrelor (Brilinta) : indication : co-administered with low-dose acetylsalicylic acid (ASA: 75-150 mg), is indicated for the secondary prevention of atherothrombotic events in patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event.

    Clinical review report. Ticagrelor (Brilinta) : indication : co-administered with low-dose acetylsalicylic acid (ASA: 75-150 mg), is indicated for the secondary prevention of ather...

    Published 2016
    Full text
    Electronic eBook
    Save to List
    Saved in:
  13. 13
    Efficacy and safety of angiotensin receptor blockers alone and in combination with diuretics in patients with hypertension, heart failure or diabetic nephropathy

    Efficacy and safety of angiotensin receptor blockers alone and in combination with diuretics in patients with hypertension, heart failure or diabetic nephropathy by Ringerike, Tove, Reikvam, Åsmund, Gjertsen, Marianne Klemp

    Published 2008
    Full text
    Electronic eBook
    Save to List
    Saved in:
  14. 14
    Clinical review report. Safinamide (Onstryv) (Valeo Pharma Inc.) : indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing "off" episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD.

    Clinical review report. Safinamide (Onstryv) (Valeo Pharma Inc.) : indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of...

    Version: final (with redactions).
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  15. 15
    CADTH Canadian Drug Expert Committee recommendation. Safinamide (Onstryv -- Valeo Pharma Inc.) : indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson's disease (PD) in patients experiencing "OFF" episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD.

    CADTH Canadian Drug Expert Committee recommendation. Safinamide (Onstryv -- Valeo Pharma Inc.) : indication: for add-on therapy to a regimen that includes levodopa for the treatmen...

    Version: 1.0.
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:
  16. 16
    Pharmacoeconomic review report. Safinamide (Onstryv) (Valeo Pharma Inc.) : indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson disease (PD) in patients experiencing "OFF" episodes while on a stable dose of levodopa. Safinamide has not been shown to be effective as monotherapy for the treatment of PD.

    Pharmacoeconomic review report. Safinamide (Onstryv) (Valeo Pharma Inc.) : indication: for add-on therapy to a regimen that includes levodopa for the treatment of the signs and sym...

    Final (with redactions).
    Published 2020
    Full text
    Electronic eBook
    Save to List
    Saved in:

Search Tools: